Vaishali Pharma valuation

·UnclassifiedChart ›
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026
Price multiples — at each FY-end close
10.04×—
0.64×—
0.41×—
Enterprise multiples
0.57×—
14.63×—
17.02×—
Yield
10.0%—
−0.1%—
Reference — adjusted share basis
₹6.82—
₹0.68₹0.64
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VAISHALI₹6.82

Vaishali Pharma Limited

· Unclassified
₹ CrorePeersTEMBOTOTALOSWALSEEDSGROBTEABEARDSELLHINDCONCROWNARTNIRMANMcap ₹44.5 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————10.04
P/B————0.64
P/Sales————0.41
Enterprise Multiples
EV/Sales————0.57
EV/EBITDA————14.63
EV/EBIT————17.02
Yield
Earnings Yield %————9.96
FCF Yield %————-0.05
Reference — adjusted share basis
Price (FY-end close, adj.)————6.82
EPS (adj.)———0.640.68
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.